TRD2

TRD2 is a novel proteolysis targeting chimera (PROTAC) designed to degrade RAD51 recombinase. It has demonstrated the ability to reduce RAD51 protein levels and inhibit cell proliferation in multiple myeloma (MM) cell lines, including those resistant to existing treatments like lenalidomide and dexamethasone. In preclinical in vivo studies, TRD2 showed synergistic effects with the chemotherapy drug cisplatin in inhibiting tumor growth in lenalidomide-resistant MM xenograft models without significant toxicity. By targeting RAD51, TRD2 aims to enhance the efficacy of DNA-damaging treatments and overcome drug resistance in MM.

Other names

Targeted RAD51 degradation 2